JP2018507191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507191A5 JP2018507191A5 JP2017539592A JP2017539592A JP2018507191A5 JP 2018507191 A5 JP2018507191 A5 JP 2018507191A5 JP 2017539592 A JP2017539592 A JP 2017539592A JP 2017539592 A JP2017539592 A JP 2017539592A JP 2018507191 A5 JP2018507191 A5 JP 2018507191A5
- Authority
- JP
- Japan
- Prior art keywords
- carbocyclyl
- alkyl
- group
- independently selected
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 130
- 125000000217 alkyl group Chemical group 0.000 claims description 124
- 125000001475 halogen functional group Chemical group 0.000 claims description 116
- 150000001875 compounds Chemical class 0.000 claims description 94
- 125000000623 heterocyclic group Chemical group 0.000 claims description 92
- 125000004043 oxo group Chemical group O=* 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 62
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 125000000304 alkynyl group Chemical group 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 102100035222 Transcription initiation factor TFIID subunit 1 Human genes 0.000 claims description 26
- 201000009030 Carcinoma Diseases 0.000 claims description 24
- 101000596093 Homo sapiens Transcription initiation factor TFIID subunit 1 Proteins 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 24
- 206010039491 Sarcoma Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- -1 R f Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- 201000004253 NUT midline carcinoma Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 8
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 230000003511 endothelial effect Effects 0.000 claims description 8
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 201000003120 testicular cancer Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010000830 Acute leukaemia Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 201000009047 Chordoma Diseases 0.000 claims description 4
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 4
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 4
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 4
- 208000000172 Medulloblastoma Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 4
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000007641 Pinealoma Diseases 0.000 claims description 4
- 208000008601 Polycythemia Diseases 0.000 claims description 4
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 201000010208 Seminoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 208000004064 acoustic neuroma Diseases 0.000 claims description 4
- 201000011186 acute T cell leukemia Diseases 0.000 claims description 4
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 208000024207 chronic leukemia Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 4
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 4
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 4
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000002409 gliosarcoma Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000025750 heavy chain disease Diseases 0.000 claims description 4
- 201000002222 hemangioblastoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 4
- 230000001926 lymphatic effect Effects 0.000 claims description 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 4
- 201000000564 macroglobulinemia Diseases 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000025189 neoplasm of testis Diseases 0.000 claims description 4
- 201000008026 nephroblastoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 4
- 201000010198 papillary carcinoma Diseases 0.000 claims description 4
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000010485 smooth muscle tumor Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000004243 sweat Anatomy 0.000 claims description 4
- 201000008753 synovium neoplasm Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 0 CCOC(*C(C(c1cc(N)ccc1)(C#C1)O)(F)F)c2c(C)[n]c3c2C1=CN(C)C3=O Chemical compound CCOC(*C(C(c1cc(N)ccc1)(C#C1)O)(F)F)c2c(C)[n]c3c2C1=CN(C)C3=O 0.000 description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- IQMAPSPJMJBMDE-UHFFFAOYSA-N CC#CC(CCN1C)(C1=O)O Chemical compound CC#CC(CCN1C)(C1=O)O IQMAPSPJMJBMDE-UHFFFAOYSA-N 0.000 description 2
- YLTBELHWTNPGRW-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCC1C=CC(C)=CC1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCC1C=CC(C)=CC1)=O)=CN(C)C2=O)O YLTBELHWTNPGRW-UHFFFAOYSA-N 0.000 description 2
- RAJGCIKQGOENJW-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(C(F)(F)F)cccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(C(F)(F)F)cccc1)=O)=CN(C)C2=O)O RAJGCIKQGOENJW-UHFFFAOYSA-N 0.000 description 2
- XOLLFMCFALREEU-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(CO)cccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1c(CO)cccc1)=O)=CN(C)C2=O)O XOLLFMCFALREEU-UHFFFAOYSA-N 0.000 description 2
- HFYQNRSYAWQQRR-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cc(C)ccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cc(C)ccc1)=O)=CN(C)C2=O)O HFYQNRSYAWQQRR-UHFFFAOYSA-N 0.000 description 2
- MSFKCFKDHJSNQB-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1C#N)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1C#N)=O)=CN(C)C2=O)O MSFKCFKDHJSNQB-UHFFFAOYSA-N 0.000 description 2
- SAKYLTWEJWVZAV-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1F)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1F)=O)=CN(C)C2=O)O SAKYLTWEJWVZAV-UHFFFAOYSA-N 0.000 description 2
- AVNTZJIUDHCKNG-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1OC)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccccc1OC)=O)=CN(C)C2=O)O AVNTZJIUDHCKNG-UHFFFAOYSA-N 0.000 description 2
- NYCGYYJZUVZQTI-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cccnc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1cccnc1)=O)=CN(C)C2=O)O NYCGYYJZUVZQTI-UHFFFAOYSA-N 0.000 description 2
- POLAKSSHSXWZGI-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccncc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ccncc1)=O)=CN(C)C2=O)O POLAKSSHSXWZGI-UHFFFAOYSA-N 0.000 description 2
- AJJOEXOTNASJST-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ncccc1)=O)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1C(OCc1ncccc1)=O)=CN(C)C2=O)O AJJOEXOTNASJST-UHFFFAOYSA-N 0.000 description 2
- OKEVXNFLBCGCIO-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(C3COCC3)[o]1)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(C3COCC3)[o]1)=CN(C)C2=O)O OKEVXNFLBCGCIO-UHFFFAOYSA-N 0.000 description 2
- CILXKLDXJWNCPX-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(CN(C)C)[o]1)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc(CN(C)C)[o]1)=CN(C)C2=O)O CILXKLDXJWNCPX-UHFFFAOYSA-N 0.000 description 2
- OQUROCJCZCKXKM-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1C(OCc1ncc[s]1)=O)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1C(OCc1ncc[s]1)=O)=CN(C)C2=O)O OQUROCJCZCKXKM-UHFFFAOYSA-N 0.000 description 2
- ZTRBROBBXVORHK-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1CC1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1CC1)O)=CN(C)C2=O)=O ZTRBROBBXVORHK-UHFFFAOYSA-N 0.000 description 2
- COMPRHAFQLQOPF-UHFFFAOYSA-N Cc1c(C(OCc2c(C)cccc2)=O)c(C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C2=O)c2[nH]1 Chemical compound Cc1c(C(OCc2c(C)cccc2)=O)c(C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C2=O)c2[nH]1 COMPRHAFQLQOPF-UHFFFAOYSA-N 0.000 description 2
- RYWWAEDUMRXXEI-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cc(-c(cccc2)c2OC)ccc1)O Chemical compound CC#CC(C(F)(F)F)(c1cc(-c(cccc2)c2OC)ccc1)O RYWWAEDUMRXXEI-UHFFFAOYSA-N 0.000 description 1
- ZAVOCVZBZQKNKE-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cc(-c2cnccc2)ccc1)O Chemical compound CC#CC(C(F)(F)F)(c1cc(-c2cnccc2)ccc1)O ZAVOCVZBZQKNKE-UHFFFAOYSA-N 0.000 description 1
- AIYYJCAJGGLCJD-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cc(C(N)=O)ccc1)O Chemical compound CC#CC(C(F)(F)F)(c1cc(C(N)=O)ccc1)O AIYYJCAJGGLCJD-UHFFFAOYSA-N 0.000 description 1
- BBXFEKJFMMPSFU-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cccc(N2CCOCC2)c1)O Chemical compound CC#CC(C(F)(F)F)(c1cccc(N2CCOCC2)c1)O BBXFEKJFMMPSFU-UHFFFAOYSA-N 0.000 description 1
- DSSZEQSNKPWVIJ-UHFFFAOYSA-N CC#CC(C(F)(F)F)(c1cccc(Oc2ccccc2)c1)O Chemical compound CC#CC(C(F)(F)F)(c1cccc(Oc2ccccc2)c1)O DSSZEQSNKPWVIJ-UHFFFAOYSA-N 0.000 description 1
- SVBRMILORLIJCN-UHFFFAOYSA-N CC#CC(CC1)(c2c1cccn2)O Chemical compound CC#CC(CC1)(c2c1cccn2)O SVBRMILORLIJCN-UHFFFAOYSA-N 0.000 description 1
- GHIBGXUHDGMVQN-UHFFFAOYSA-N CC#CC(c(cccc1)c1N1C)(C1=O)O Chemical compound CC#CC(c(cccc1)c1N1C)(C1=O)O GHIBGXUHDGMVQN-UHFFFAOYSA-N 0.000 description 1
- UTISCLIDFORRJP-UHFFFAOYSA-N CC#CC1(CCCCC1)O Chemical compound CC#CC1(CCCCC1)O UTISCLIDFORRJP-UHFFFAOYSA-N 0.000 description 1
- FQTRQGLOMXZYRW-UHFFFAOYSA-N CC#CC1(CCOCC1)O Chemical compound CC#CC1(CCOCC1)O FQTRQGLOMXZYRW-UHFFFAOYSA-N 0.000 description 1
- GNJQQUZKWGDHCB-UHFFFAOYSA-N CC#Cc1cccc(O)c1 Chemical compound CC#Cc1cccc(O)c1 GNJQQUZKWGDHCB-UHFFFAOYSA-N 0.000 description 1
- CDRHEAQGERWKJT-UHFFFAOYSA-N CC(C)(C#CC(c1c2[nH]c(C)c1-c1nnc(C)[o]1)=CN(C)C2=O)O Chemical compound CC(C)(C#CC(c1c2[nH]c(C)c1-c1nnc(C)[o]1)=CN(C)C2=O)O CDRHEAQGERWKJT-UHFFFAOYSA-N 0.000 description 1
- QTQNNPUOOYLCIW-UHFFFAOYSA-N CC(C)(C)NC(N(C)C)=O Chemical compound CC(C)(C)NC(N(C)C)=O QTQNNPUOOYLCIW-UHFFFAOYSA-N 0.000 description 1
- ZTKSREVAFIAEHL-UHFFFAOYSA-N CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 ZTKSREVAFIAEHL-UHFFFAOYSA-N 0.000 description 1
- OZWRPGVUTGFIAO-UHFFFAOYSA-N CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 OZWRPGVUTGFIAO-UHFFFAOYSA-N 0.000 description 1
- ILWOKHFPQCOUFS-UHFFFAOYSA-N CC(C)Cc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)Cc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 ILWOKHFPQCOUFS-UHFFFAOYSA-N 0.000 description 1
- PDUSWJORWQPNRP-UHFFFAOYSA-N CC(C)NC(C)=O Chemical compound CC(C)NC(C)=O PDUSWJORWQPNRP-UHFFFAOYSA-N 0.000 description 1
- DUDIPXYIILKDKL-UHFFFAOYSA-N CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 DUDIPXYIILKDKL-UHFFFAOYSA-N 0.000 description 1
- WVBZAVCHGVOIMZ-UHFFFAOYSA-N CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)[F]CCOC(c2c(C)[nH]c4c2C(C#CC(C2F)(c5ccccc5C2=C)O)=CN(C)C4=O)=O)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)[F]CCOC(c2c(C)[nH]c4c2C(C#CC(C2F)(c5ccccc5C2=C)O)=CN(C)C4=O)=O)(c2ccccc2)O)=CN(C)C3=O)[o]1 WVBZAVCHGVOIMZ-UHFFFAOYSA-N 0.000 description 1
- NCNRTTXMYNBOSU-UHFFFAOYSA-N CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CC(C)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 NCNRTTXMYNBOSU-UHFFFAOYSA-N 0.000 description 1
- ZDUBCPAENRAHNV-UHFFFAOYSA-N CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc[o]1)=CN(C)C2=O)O Chemical compound CC(C1CC1)(C#CC(c1c2[nH]c(C)c1-c1nnc[o]1)=CN(C)C2=O)O ZDUBCPAENRAHNV-UHFFFAOYSA-N 0.000 description 1
- LWDCCYHOADNXGR-UHFFFAOYSA-N CC(C1CCOCC1)(C#CC)O Chemical compound CC(C1CCOCC1)(C#CC)O LWDCCYHOADNXGR-UHFFFAOYSA-N 0.000 description 1
- IUUDENXUSWKSSU-OFARCZAXSA-N CC(CCc1cc([C@@](C)(C#CC(c2c3[nH]c(C)c2-c2nnc(C4CC4)[o]2)=CN(C)C3=O)O)n[o]1)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 Chemical compound CC(CCc1cc([C@@](C)(C#CC(c2c3[nH]c(C)c2-c2nnc(C4CC4)[o]2)=CN(C)C3=O)O)n[o]1)c1nnc(-c2c(C)[nH]c3c2C(C#CC(C(F)(F)F)(c2ccccc2)O)=CN(C)C3=O)[o]1 IUUDENXUSWKSSU-OFARCZAXSA-N 0.000 description 1
- JAUWMBGLPFUMJR-UHFFFAOYSA-N CC(c1ccccc1)(C#CC)O Chemical compound CC(c1ccccc1)(C#CC)O JAUWMBGLPFUMJR-UHFFFAOYSA-N 0.000 description 1
- NEPLNECCNNUJRX-UHFFFAOYSA-N CCN(CC1)CCC1(C#CC(c1c2[nH]c(C)c1C(OCC)=O)=CN(C)C2=O)O Chemical compound CCN(CC1)CCC1(C#CC(c1c2[nH]c(C)c1C(OCC)=O)=CN(C)C2=O)O NEPLNECCNNUJRX-UHFFFAOYSA-N 0.000 description 1
- HAYMIDKYYVULDW-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c(cc1)ccc1N(C)C)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c(cc1)ccc1N(C)C)O)=CN(C)C2=O)=O HAYMIDKYYVULDW-UHFFFAOYSA-N 0.000 description 1
- GMYODIBKFOKUSD-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cccc(Oc3ccccc3)c1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cccc(Oc3ccccc3)c1)O)=CN(C)C2=O)=O GMYODIBKFOKUSD-UHFFFAOYSA-N 0.000 description 1
- XCRRPGBTFDGFHY-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cnccc1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C(F)(F)F)(c1cnccc1)O)=CN(C)C2=O)=O XCRRPGBTFDGFHY-UHFFFAOYSA-N 0.000 description 1
- PZZZGCXHKXMEIQ-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1COCC1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C)(C1COCC1)O)=CN(C)C2=O)=O PZZZGCXHKXMEIQ-UHFFFAOYSA-N 0.000 description 1
- XXSMVTRJNJTNEP-UHFFFAOYSA-N CCOC(c1c(C)[nH]c2c1C(C#CC(C1F)(c3ccccc3C1=C)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#CC(C1F)(c3ccccc3C1=C)O)=CN(C)C2=O)=O XXSMVTRJNJTNEP-UHFFFAOYSA-N 0.000 description 1
- KGANURWDWKINIY-FQEVSTJZSA-N CCOC(c1c(C)[nH]c2c1C(C#C[C@@](C)(c1ncccn1)O)=CN(C)C2=O)=O Chemical compound CCOC(c1c(C)[nH]c2c1C(C#C[C@@](C)(c1ncccn1)O)=CN(C)C2=O)=O KGANURWDWKINIY-FQEVSTJZSA-N 0.000 description 1
- JUUMTYGPWSCEQD-UHFFFAOYSA-N CCc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 Chemical compound CCc1nnc(-c2c(C)[nH]c3c2C(C#CC(C)(C2CC2)O)=CN(C)C3=O)[o]1 JUUMTYGPWSCEQD-UHFFFAOYSA-N 0.000 description 1
- CULPBDKFGLEGBW-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C)[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C)[o]1 CULPBDKFGLEGBW-UHFFFAOYSA-N 0.000 description 1
- VHIOSRHANFWGLA-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C2CC2)[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(C2CC2)[o]1 VHIOSRHANFWGLA-UHFFFAOYSA-N 0.000 description 1
- MLHPFLGFGSTYNO-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(CCN(C)C)[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc(CCN(C)C)[o]1 MLHPFLGFGSTYNO-UHFFFAOYSA-N 0.000 description 1
- XEXSQVGAQDRAMI-UHFFFAOYSA-N Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc[o]1 Chemical compound Cc([nH]c1c2C(C#CC(C(F)(F)F)(c3ccccc3)O)=CN(C)C1=O)c2-c1nnc[o]1 XEXSQVGAQDRAMI-UHFFFAOYSA-N 0.000 description 1
- UNPXNUFUHNWFBO-UHFFFAOYSA-N Cc(cccc1)c1-c1cccc(C(C(F)(F)F)(C#CC)O)c1 Chemical compound Cc(cccc1)c1-c1cccc(C(C(F)(F)F)(C#CC)O)c1 UNPXNUFUHNWFBO-UHFFFAOYSA-N 0.000 description 1
- NZIPEXQUTDPBDQ-UHFFFAOYSA-N Cc1cc(C(C(F)(F)F)(C#CC)O)cc(O)c1 Chemical compound Cc1cc(C(C(F)(F)F)(C#CC)O)cc(O)c1 NZIPEXQUTDPBDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109522P | 2015-01-29 | 2015-01-29 | |
| US62/109,522 | 2015-01-29 | ||
| PCT/US2016/015450 WO2016123391A1 (en) | 2015-01-29 | 2016-01-28 | Therapeutic compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507191A JP2018507191A (ja) | 2018-03-15 |
| JP2018507191A5 true JP2018507191A5 (OSRAM) | 2019-03-07 |
| JP6709792B2 JP6709792B2 (ja) | 2020-06-17 |
Family
ID=55361971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539592A Active JP6709792B2 (ja) | 2015-01-29 | 2016-01-28 | 治療用化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10202378B2 (OSRAM) |
| EP (1) | EP3250571B1 (OSRAM) |
| JP (1) | JP6709792B2 (OSRAM) |
| CN (1) | CN107531692B (OSRAM) |
| WO (1) | WO2016123391A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2018037058A1 (en) * | 2016-08-24 | 2018-03-01 | F. Hoffmann-La Roche Ag | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use |
| EP3504206B1 (en) * | 2016-08-24 | 2022-03-23 | F. Hoffmann-La Roche AG | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use |
| US11171132B2 (en) * | 2019-10-03 | 2021-11-09 | Globalfoundries U.S. Inc. | Bi-directional breakdown silicon controlled rectifiers |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
| CN120136817A (zh) * | 2025-05-16 | 2025-06-13 | 安徽泽升科技股份有限公司 | 一种氧杂环丁烷-3-甲醇和氧杂环丁烷-3-甲醛的制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| MX9700535A (es) | 1994-07-21 | 1997-04-30 | Akzo Nobel Nv | Formulaciones de peroxido de cetona ciclico. |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DK0980244T3 (da) | 1997-05-06 | 2003-09-29 | Wyeth Corp | Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CA2306155A1 (en) | 1997-11-06 | 1999-05-20 | Philip Frost | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| WO2007058392A1 (ja) | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2014125408A2 (en) | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| BR112015022674A2 (pt) | 2013-03-11 | 2017-07-18 | Abbvie Inc | inibidores de bromodomínio |
| KR20150126696A (ko) * | 2013-03-12 | 2015-11-12 | 애브비 인코포레이티드 | 디하이드로-피롤로피리디논 브로모도메인 억제제 |
| JP6419735B2 (ja) | 2013-03-12 | 2018-11-07 | アッヴィ・インコーポレイテッド | 四環系ブロモドメイン阻害剤 |
| CN104211639A (zh) * | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| EA201690007A1 (ru) * | 2013-06-12 | 2016-04-29 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| SG11201510678TA (en) | 2013-06-28 | 2016-01-28 | Abbvie Inc | Bromodomain inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| KR20240134245A (ko) | 2014-04-23 | 2024-09-06 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| CN107108613B (zh) | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| US9695200B2 (en) | 2015-01-23 | 2017-07-04 | Confluence Life Sciences, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
-
2016
- 2016-01-28 JP JP2017539592A patent/JP6709792B2/ja active Active
- 2016-01-28 EP EP16704984.0A patent/EP3250571B1/en active Active
- 2016-01-28 CN CN201680019098.2A patent/CN107531692B/zh active Active
- 2016-01-28 WO PCT/US2016/015450 patent/WO2016123391A1/en not_active Ceased
-
2017
- 2017-07-24 US US15/658,213 patent/US10202378B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507191A5 (OSRAM) | ||
| JP2017530176A5 (OSRAM) | ||
| JP2018510851A5 (OSRAM) | ||
| JP2017530984A5 (OSRAM) | ||
| JP2016510748A5 (OSRAM) | ||
| JP2019516759A5 (OSRAM) | ||
| RU2015142102A (ru) | Соединение для лечения рака | |
| JP2017537100A5 (OSRAM) | ||
| JP2017533250A5 (OSRAM) | ||
| JP2017526696A5 (OSRAM) | ||
| JP2016529312A5 (OSRAM) | ||
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| SG11201804348SA (en) | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug | |
| JP2019517487A5 (OSRAM) | ||
| JP2017500334A5 (OSRAM) | ||
| JP2019529444A5 (OSRAM) | ||
| JP2014513046A5 (OSRAM) | ||
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2019522055A5 (OSRAM) | ||
| JP2018501287A5 (OSRAM) | ||
| JP2017525740A5 (OSRAM) | ||
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| MX2020007722A (es) | Inhibidores de endonucleasa cap-dependientes. | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака |